After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

IRVINE, Calif., April 14, 2025--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up market rivalry with Abbott. Edwards’ device, dubbed Sapien M3 ...

The condition is more common in women and younger patients with valve disorder and can, in the worst case, lead to sudden cardiac arrest. Mitral annular disjunction, MAD, is a heart abnormality in ...

Image credit: Shutterstock/Steve Cukrov. Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up market rivalry with Abbott. Edwards ...

[5] In these instances the calcium deposits are thought to alter the structure and motion of the valve leaflets and thus prevent the normal opening of the aortic cusps. The cause of this ...

2010;8(8):879-885. These examples highlight the importance of host immune defenses in protecting against Gram-negative endocarditis. With a changing demographic profile, notably a growing elderly ...

Nitinol is commonly used in replacement heart valve frames, but that’s not how the new Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system uses nitinol’s shape memory ...

Edwards is building a multi-product TMTT portfolio. The company received CE marks for its Pascal mitral and tricuspid valve repair devices in 2019 and 2020, respectively, and for the Evoque tricuspid ...

The Sapien M3 heart valve [Image courtesy of Edwards Lifesciences] Edwards Lifesciences (NYSE: EW) + announced today that it received CE mark approval for its Sapien M3 mitral valve replacement ...